StockData
ImmuCell Corp logo

ImmuCell Corp (ICCC) stock

ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/303% above fair value
$11.33−0.09 (-0.79%)

Close on Nov 17, 2026Market cap $102.90MP/E 141.6Yield –

ImmuCell operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

ImmuCell's operating cash flow for the twelve months ending Jun 30, 2026 was $5.89M, up 132.6% year over year. For fiscal 2025 it was $2.48M, up 591.6% from the year before. Over ten years it grew -1.6% a year on average. The highest annual figure on record is $2.90M in fiscal 2015.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.48M+591.6%
FY2024Dec 31, 2024$357.90K–
FY2023Dec 31, 2023-$4.67M–
FY2022Dec 31, 2022-$1.54M-261.8%
FY2021Dec 31, 2021$954.17K-27.5%
FY2020Dec 31, 2020$1.32M+463.4%
FY2019Dec 31, 2019$233.51K–
FY2018Dec 31, 2018-$373.40K-131.8%
FY2017Dec 31, 2017$1.18M–
FY2016Dec 31, 2016-$222.31K-107.7%
FY2015Dec 31, 2015$2.90M+859.2%
FY2014Dec 31, 2014$302.36K-72.5%
FY2013Dec 31, 2013$1.10M+219.0%
FY2012Dec 31, 2012$344.39K–
FY2011Dec 31, 2011-$37.32K–
FY2010Dec 31, 2010-$808.61K–
FY2009Dec 31, 2009-$109.67K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$3.02M+88.5%
Q1 FY2026Mar 31, 2026$3.57M+127.0%
Q4 FY2025Dec 31, 2025$482.54K–
Q3 FY2025Sep 30, 2025-$1.18M–
Q2 FY2025Jun 30, 2025$1.60M+175.3%
Q1 FY2025Mar 31, 2025$1.57M+276.1%
Q4 FY2024Dec 31, 2024-$3.05K–
Q3 FY2024Sep 30, 2024-$639.33K–
Q2 FY2024Jun 30, 2024$581.78K–
Q1 FY2024Mar 31, 2024$418.51K–
Q4 FY2023Dec 31, 2023-$723.07K–
Q3 FY2023Sep 30, 2023-$507.75K–
Q2 FY2023Jun 30, 2023-$681.43K-282.5%
Q1 FY2023Mar 31, 2023-$2.76M-532.6%
Q4 FY2022Dec 31, 2022-$1.30M-320.8%
Q3 FY2022Sep 30, 2022-$1.26M-585.7%
Q2 FY2022Jun 30, 2022$373.46K-48.9%
Q1 FY2022Mar 31, 2022$638.54K–
Q4 FY2021Dec 31, 2021$587.89K+276.3%
Q3 FY2021Sep 30, 2021$258.99K–
Q2 FY2021Jun 30, 2021$730.83K-24.6%
Q1 FY2021Mar 31, 2021-$623.55K-172.7%
Q4 FY2020Dec 31, 2020$156.25K–
Q3 FY2020Sep 30, 2020-$667.33K–
Q2 FY2020Jun 30, 2020$969.20K–
Q1 FY2020Mar 31, 2020$857.45K+26.6%
Q4 FY2019Dec 31, 2019-$46.62K–
Q3 FY2019Sep 30, 2019-$66.41K–
Q2 FY2019Jun 30, 2019-$330.66K-1658.3%
Q1 FY2019Mar 31, 2019$677.20K+171.2%
Q4 FY2018Dec 31, 2018-$138.35K-141.8%
Q3 FY2018Sep 30, 2018-$505.94K–
Q2 FY2018Jun 30, 2018$21.22K–
Q1 FY2018Mar 31, 2018$249.66K-80.1%
Q4 FY2017Dec 31, 2017$330.71K–
Q3 FY2017Sep 30, 2017-$255.12K–
Q2 FY2017Jun 30, 2017-$155.12K–
Q1 FY2017Mar 31, 2017$1.26M–
Q4 FY2016Dec 31, 2016-$372.04K–
Q3 FY2016Sep 30, 2016-$16.33K–

More ImmuCell figures

See a number that looks wrong?